Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAK®, a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21, now being evaluated in multiple clinical trials. CAVATAK binds to specific receptor proteins highly expressed on a range of tumour cell types, and acts to destroy local as well as metastatic cancer cells through cell lysis and the potential generation of a specific immune response against the cancer cells.
CAVATAK-induced changes in the tumour microenvironment suggest a strong local and systemic anti-tumour response, particularly when used in combination with checkpoint inhibitors. These changes include an increase in immune cell infiltration and the up-regulation of immune-checkpoint molecules such as PD-L1. Through these selective mechanisms of action, our therapies are designed to provide greater tolerability and efficacy, offering hope and potential clinical benefit to patients with cancers that are difficult to treat with current therapeutic approaches.
CAVATAK has potential activity in a range of cancer types including melanoma, lung, and bladder cancers. We have several ongoing clinical trials exploring CAVATAK’s potential in combination settings including with KEYTRUDA® and YERVOY® . In addition we have completed a Phase 2 clinical trial of intra-tumourally administered CAVATAK as a monotherapy in Late stage Melanoma and a Phase 1 trial in superficial bladder cancer.
Headquartered in Sydney, Australia, Viralytics is a public company listed on the Australian Stock Exchange (ASX: VLA) and quoted on the OTCQX market (VRACY) in the United States. Our Research and Development facility is located in the Hunter Medical Research Institute (HMRI) building in Newcastle, Australia. Clinical and other development activities are supported by a range of global partners and consultants.